Anova today announced it has expanded it’s site network to facilitate just-in-time access to COVID-19 investigational products through clinical trials and compassionate use.

Anova is now supporting a range of biopharmaceutical companies with anti-body, anti-viral and cell-based therapies in their preparation, testing and access for COVID-19 patients, including the preparation of emergency IND submissions, designing and implemented clinical programs, and also supporting emergency access to these promising investigational products for both clinical trials and compassionate use, in a just-in-time fashion. This includes product delivery in an emergency setting.

Anova is a technology company, with a platform designed to change the way biopharmaceutical companies develop treatments from one where sites are activated in the hope they find patients, to one where patients can participate wherever they receive care. The rapid initiation of clinical programs for COVID-19 and collection of high quality data is critical in this pandemic.

Contact our team to find out more about how we are helping sponsors and manufacturers accelerate development of promising products in response to the COVID-19 pandemic.